A LANDMARK RESPONSE ANALYSIS TO DETERMINE COST-EFFECTIVENESS OF THIRD-LINE NIVOLUMAB MONOTHERAPY FOR SMALL CELL LUNG CANCER

被引：0
|
作者：
Smare, C. [1 ]
Dave, K. [1 ]
Juarez-Garcia, A. [2 ]
Schoenherr, N. [2 ]
Abraham, P. [3 ]
Penrod, J. R. [3 ]
Camidge, D. R. [4 ]
Yuan, Y. [3 ]
机构：
[1] PAREXEL Int, London, England
[2] Bristol Myers Squibb Pharmaceut Ltd, London, England
[3] Bristol Myers Squibb, Princeton, NJ USA
[4] Univ Colorado Denver, Aurora, CO USA
来源：
VALUE IN HEALTH | 2019年 / 22卷
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN236
引用
收藏
页码：S481 / S481
页数：1
相关论文
共 50 条
  • [31] Retrospective analysis of third-line chemotherapy in advanced non-small cell lung cancer
    Tatli, Ali Murat
    Arslan, Deniz
    Uysal, Mukremin
    Goksu, Sema Sezgin
    Gunduz, Seyda Gulenay
    Coskun, Hasan Senol
    Ozdogan, Mustafa
    Savas, Burhan
    Bozcuk, Hakan Sat
    [J]. JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2015, 11 (04) : 805 - 809
  • [32] Durvalumab monotherapy as a third-line treatment for extensive-stage small-cell lung cancer: a case report
    Zhou, Qinfei
    Zhao, Jiazheng
    Wang, Jie
    Bao, Guanai
    Gong, Li-Yan
    [J]. ANNALS OF PALLIATIVE MEDICINE, 2020, 9 (04) : 2386 - 2392
  • [33] Cost-Effectiveness Analysis of Nivolumab Plus Ipilimumab in the First-Line Treatment of Metastatic Non-Small Cell Lung Cancer in the United States
    Berling, M.
    Chaudhary, M. A.
    Yuan, Y.
    Varol, N.
    Dale, P.
    Testa, E.
    Klint, J.
    Lee, A.
    Lubinga, S. J.
    Penrod, J. R.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (01) : S15 - S16
  • [34] Third-line therapy in advanced non-small cell lung cancer
    Geng, Zhen Ying
    Jiao, Shun Chang
    Liu, Shi Cui
    Li, Ying
    Liu, Zhe Feng
    Zhang, Guo Qing
    Wang, Li Jie
    Qu, Feng
    [J]. JOURNAL OF BUON, 2013, 18 (04): : 899 - 907
  • [35] COST-EFFECTIVENESS OF NIVOLUMAB VS. DOCETAXEL AS SECOND-LINE TREATMENT FOR ADVANCED NON-SMALL CELL LUNG CANCER
    Shah, S.
    Matthews, S. E.
    Sarasani, S.
    Noel, S.
    Blanchette, C. M.
    [J]. VALUE IN HEALTH, 2016, 19 (07) : A732 - A732
  • [36] Effectiveness and Cost-Effectiveness Profile of Second-Line Treatments with Nivolumab, Pembrolizumab and Atezolizumab in Patients with Advanced Non-Small Cell Lung Cancer
    Franchi, Matteo
    Pellegrini, Giacomo
    Corrao, Giovanni
    [J]. PHARMACEUTICALS, 2022, 15 (04)
  • [37] Prevalence and effectiveness of third-line therapy for advanced non-small cell lung cancer (A-NSCLC)
    Ferreira, Catarina
    Fernandes, Ligia
    Figueiredo, Ana
    Barata, Fernando
    [J]. EUROPEAN RESPIRATORY JOURNAL, 2012, 40
  • [38] The Cost-Effectiveness of Lorlatinib Versus Chemotherapy as a Second- or Third-Line Treatment in Anaplastic Lymphoma Kinase (ALK)-Positive Non-small-cell Lung Cancer in Sweden
    Nilsson, Fredrik O. L.
    Asanin, Sandra T.
    Masters, Elizabeth T.
    Iadeluca, Laura
    Almond, Chrissy
    Cooper, Miranda
    Smith, Sarah
    [J]. PHARMACOECONOMICS, 2021, 39 (08) : 941 - 952
  • [39] Nivolumab Versus Docetaxel for Previously Treated Advanced Non-Small Cell Lung Cancer in China: A Cost-Effectiveness Analysis
    Liu, Qiao
    Luo, Xia
    Peng, Liubao
    Yi, Lidan
    Wan, Xiaomin
    Zeng, Xiaohui
    Tan, Chongqing
    [J]. CLINICAL DRUG INVESTIGATION, 2020, 40 (02) : 129 - 137
  • [40] Nivolumab Versus Docetaxel for Previously Treated Advanced Non-Small Cell Lung Cancer in China: A Cost-Effectiveness Analysis
    Qiao Liu
    Xia Luo
    Liubao Peng
    Lidan Yi
    Xiaomin Wan
    Xiaohui Zeng
    Chongqing Tan
    [J]. Clinical Drug Investigation, 2020, 40 : 129 - 137
12345